Cooperation between BioVisioN and Roche Diagnostics
Roche Diagnostics is validating new marker candidates for diagnosis of Alzheimer Disease
Since entering into a cooperation project with Roche Diagnostics GmbH of Mannheim in 1999, Hanover-based biotechnology firm BioVisioN has identified a number of proteins that may enable early diagnosis of Alzheimer's disease and distinguish it from other forms of dementia. The cooperation between BioVisioN and Roche Diagnostics GmbH is therefore now entering a new phase.
BioVisioN began investigating the volumes of small proteins (peptides) in cerebrospinal fluid in 1999. Working together with Roche Diagnostics, this procedure was used successfully in 2000 and 2001 on samples taken from Alzheimer's sufferers, patients with other forms of dementia and control patients. This enabled molecules to be identified that changed content specifically in the cerebrospinal fluid of Alzheimer's patients. Several patents have been filed on the basis of these findings, and another is currently being registered. Having assessed the data, Roche Diagnostics has now decided to test large groups of patients for the presence of the most promising of these peptides in serum, and it is currently developing an appropriate testing system.
More than a million people are afflicted with dementia in Germany alone, more than half of them in the form of Alzheimer's Disease. This is typically found in elderly people and - due to its clinical phenotype - often only diagnosed at an advanced stage. The different types of dementia require different treatment, which in the case of Alzheimer's in particular is only effective at a very early stage. The medicines currently available are of no use when prescribed at an advanced stage, and treatment focuses largely on adapting the patient's living conditions and surroundings. As a result, feverish research is underway to find a way to diagnose Alzheimer's specifically, and this reliably and even at an early stage.
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Sobering-up_station
DuPont, Athenix Collaborate to Advance Insect Control in Corn, Soybeans
DNA duplication: a mechanism for ‘survival of the fittest’
History_of_poliomyelitis
Category:EC_1.16.3
